JPS59175428A - Cariostatic agent - Google Patents

Cariostatic agent

Info

Publication number
JPS59175428A
JPS59175428A JP5120383A JP5120383A JPS59175428A JP S59175428 A JPS59175428 A JP S59175428A JP 5120383 A JP5120383 A JP 5120383A JP 5120383 A JP5120383 A JP 5120383A JP S59175428 A JPS59175428 A JP S59175428A
Authority
JP
Japan
Prior art keywords
agent
lactone
streptococcus mutans
side effects
cariostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5120383A
Other languages
Japanese (ja)
Other versions
JPH0320364B2 (en
Inventor
Keiji Iguchi
井口 圭二
Masayoshi Fukuda
福田 正佳
Koichi Ogata
浩一 尾形
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KANEBO SHOKUHIN KK
Kracie Foods Ltd
Original Assignee
KANEBO SHOKUHIN KK
Kanebo Foods Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KANEBO SHOKUHIN KK, Kanebo Foods Ltd filed Critical KANEBO SHOKUHIN KK
Priority to JP5120383A priority Critical patent/JPS59175428A/en
Publication of JPS59175428A publication Critical patent/JPS59175428A/en
Publication of JPH0320364B2 publication Critical patent/JPH0320364B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom

Abstract

PURPOSE:To provide a drug for oral cavity application, useful as a cariostatic agent free from side effects and having extremely high safety, by using a lactone as an active component. CONSTITUTION:The objective agent contains a lactone (e.g. d-decalactone, d- dodecalactone, d-undecalactone, d-tridecalactone, d-tetradecalactone, etc.) as an active component. The antibacterial activity of lactone to Streptococcus mutans causing caries is relatively low compared with an antibiotic substance, erythromycin; however, there is no side effects (disturbance of the microflora in the body, emergence of resistant strain, etc.) of antibiotic substances because the compound is a high-safety flavor component used widely in food industry, etc., and the agent can be administered continuously for a long period absolutely without problems. Since the agent inhibits the growth of Streptococcus mutans at an extremely low concentration, a cariostatic effect can be attained by the use of only a slight amount of the compound. It is used as a flavor of gargle, troche, dentifrice, etc.

Description

【発明の詳細な説明】 この発明は、抗結節剤、すなわち結節を予防しまだはそ
の進行を阻止する口腔用剤に関するものである。
DETAILED DESCRIPTION OF THE INVENTION This invention relates to anti-nodule agents, oral agents that prevent and even arrest the progression of nodules.

近年、結節す々わち虫歯の罹患率は著しく増大しており
、大きな社会問題にまで発展している。
In recent years, the prevalence of nodules and tooth decay has increased significantly, and it has developed into a major social problem.

一方、これに伴って結節の原因の研究も進んでおり、現
在の定説では結節の原因は食物中の蔗糖が結節原因菌の
作用により変化を受は不溶性かつ粘着性のグルカンを生
成することにあるとされている。このようにして生成さ
れたグルカンによって結節原因菌が歯面に付着して増殖
し歯垢を形成する。そして、この歯垢をベースとしてそ
の中の細菌が糖発酵により酸を発生し、その酸により結
節が進行するのである。結節の防止には歯の抵抗性を高
める方法、蔗糖を排除するか、蔗糖に代わる甘味料を使
用する方法、蔗糖より生成する不溶性のグルカンを分解
するかまたはグルカンの生成を阻止する方法もしくは結
節原因菌を撲滅する方法等が考えられる。上記の方法に
はそれぞれ長所欠点を備えているが結節の本質が結節原
因菌による感染症であるため、この原因となる結節原因
菌を撲滅することが1蝕防止に最も効呆的であると考え
られる。上記の菌としてはストレプトコッカスミュータ
ンス(5treptococcus Mutans )
やストレプト=+ツカスサングイス(5treptoc
occus Sanguis)があげられる。結節防止
のためにこのような結節原因菌を駆逐しようとするここ
ろみはこれまでも数多くなされている。例えばペニシリ
ンやエリスロマイシン等の抗生物質、結節原因菌の細胞
壁を溶解する細胞壁溶解酵素やシクロヘキシジン等の殺
菌剤の使用がこころみられている。しかしながら、これ
らは[]腔内および腸内細菌叢の撹乱により自然の細菌
バランスを壊し、しかも副作用を惹起するという問題が
ある。このような副作用の問題の解決がなされてい々い
ため広く用いられるには致っていない。したがって、も
つかのところ結節防上のために決定的な方法がないのが
実情であり、食後、はぶらしで清掃するという物理的な
方法に勝る予防法の確立がなされていないのが現状であ
る。
Meanwhile, research into the causes of nodules is also progressing, and the current theory is that the sucrose in food undergoes changes due to the action of nodule-causing bacteria, producing insoluble and sticky glucan. It is said that there is. The glucan thus produced causes nodule-causing bacteria to adhere to the tooth surface and multiply, forming dental plaque. Using this plaque as a base, bacteria within it generate acid through sugar fermentation, and this acid causes nodules to develop. To prevent nodules, there are ways to increase tooth resistance, eliminate sucrose or use sweeteners instead of sucrose, break down insoluble glucan produced from sucrose, or prevent glucan production or nodule. Possible methods include eradicating the causative bacteria. Each of the above methods has its own advantages and disadvantages, but since the essence of nodule is an infection caused by nodule-causing bacteria, eradicating the nodule-causing bacteria is the most effective way to prevent 1st erosion. Conceivable. The above bacteria include Streptococcus mutans
Streptoc
occus Sanguis). Many attempts have been made to eliminate such nodule-causing bacteria in order to prevent nodules. For example, efforts are being made to use antibiotics such as penicillin and erythromycin, cell wall lytic enzymes that dissolve the cell walls of nodule-causing bacteria, and disinfectants such as cyclohexidine. However, these have problems in that they disrupt the natural bacterial balance by disrupting the intraluminal and intestinal flora, and also cause side effects. Since the problem of such side effects has not yet been solved, it has not been widely used. Therefore, the reality is that there is no definitive method for preventing nodules, and no preventive method has been established that is superior to the physical method of cleaning with a towel after meals. It is.

本発明者ら(d、このような事情に鑑み結節の防止を1
指して一連の研究を重ねているうち、ある種の香料に抗
菌作用があることにヒントを得て、香料を接結融剤とし
て用いられないかと厖大な数の香料を対象とし、長期間
に渡って一連の研究を進めてきた。その結果、着香料と
して用いられているラクトンが優れた結節原因菌殺菌効
果を有することを見いだしこの発明に到達した。すなわ
ち、この発明は、ラクトンからなることを特徴とする抗
帖融剤をその要旨とするものである。
In view of these circumstances, the present inventors (d.
While conducting a series of researches, he got a hint from the fact that certain fragrances have antibacterial effects, and investigated the possibility of using fragrances as binders, targeting a huge number of fragrances and conducting research over a long period of time. We have carried out a series of research over the years. As a result, it was discovered that lactone, which is used as a flavoring agent, has an excellent bactericidal effect on nodule-causing bacteria, and the present invention was achieved. That is, the gist of the present invention is an antidepressant characterized by comprising a lactone.

このように、この発明d:、副作用が全くなく安全性の
極めて高い香料成分を接融融剤として用いるところに最
大の特徴がある。
As described above, the greatest feature of this invention (d) is that an extremely safe fragrance ingredient with no side effects is used as a welding agent.

つぎに、この発明の詳細な説明する。Next, this invention will be explained in detail.

従来、天然精油や天然精油の有効成分のうちの一部のも
のには大腸菌、赤痢菌等に対する抗菌作用があるという
報告が散見されている。しかしながら、ラクトンのよう
な着香料の抗菌性に関する報告は殆ど見当らない。そこ
で、本発明者らは、まづ、第1段階として比較的汎用さ
れているラクトンを対象とじミュータンス菌に対する抗
菌活性を測定した。抗菌活性は、それぞれラクトンを5
チのアルコール溶液としくこれを供試成分とする)、こ
れを、5φの蔗糖を含有するハートインフュージョン培
地にl/l 00〜1/1000の割合(5係アルコー
ル溶液((供試成分))濃度が1/100〜l/100
0)になるように添加し、培地が固化したのち、ミュー
タンス菌(ストレプトコーカスミュータンスRIMD 
8125”001 )を穿刺接種して37°Cで72時
間以上培養し、培地中、培地表面における菌の生育を観
察して測定した。抗ミュータンス菌活性があるものは後
記の表のとおりである。抗ミュータンス菌活性があると
いうことは、供試成分を171000の割合になるよう
に添加し、37°Cで72時間以上培養した場合におい
てミュータンス閑の生育が認められないということであ
る。そして、供試成分濃度をどんどん希釈してゆき、抗
ミュータンス菌活性が認められる最少濃度(有効生育阻
止濃度)の逆数、例えば供試成分濃度が1/1000で
あるときは、その逆数の1000を抗ミュータンス菌活
性値として示した。対象用として厚朴エキス、厚朴エキ
スの有効成分であるマグノロールならびにミュータンス
菌に対する殺菌作用をもつ抗生物質エリスロマイシンを
用い同様の実験を行って、後記の表に併せて示しだ。同
表に掲げるラクトンは、抗結節用剤として知られている
厚朴エキス(特開昭57−85319参照)と同等かそ
れ以−ヒの優れた抗ミュータンス菌活性を示している。
Heretofore, there have been reports that natural essential oils and some of the active ingredients of natural essential oils have antibacterial effects against Escherichia coli, Shigella, and the like. However, there are few reports regarding the antibacterial properties of flavoring agents such as lactones. Therefore, as a first step, the present inventors measured the antibacterial activity against Streptococcus mutans using a relatively widely used lactone. The antibacterial activity of each lactone is
Add this to heart infusion medium containing 5φ sucrose at a ratio of l/l 00 to 1/1000 (5% alcohol solution (test component)). ) concentration is 1/100 to l/100
Streptococcus mutans RIMD.
8125"001) was punctured and cultured at 37°C for over 72 hours, and the growth of the bacteria in the medium and on the surface of the medium was observed and measured. Those with anti-Streptococcus mutans activity are as shown in the table below. Streptococcus mutans has anti-Streptococcus mutans activity, which means that when the test components are added at a ratio of 171,000 to 171,000 and cultured at 37°C for 72 hours or more, no growth of mutans is observed. Then, the concentration of the test component is gradually diluted, and the reciprocal of the minimum concentration (effective growth inhibitory concentration) at which anti-Streptococcus mutans activity is observed, for example, when the concentration of the test component is 1/1000, the reciprocal is determined. 1000 was shown as the anti-Streptococcus mutans activity value.Similar experiments were conducted using Atsuboku extract, Magnolol, the active ingredient of Atsubaku extract, and erythromycin, an antibiotic that has a bactericidal effect against Streptococcus mutans, as subjects. The lactones listed in the table are equivalent to or better than Koboku extract (see Japanese Patent Application Laid-open No. 57-85319), which is known as an anti-nodule agent. shows B. tans activity.

このように、この発明の接結融剤は、食品業界等で幅広
く、実際に使用されている安全性の高い香料成分からな
るため副作用は全く生じない。すなわち、この発明の抗
歯1[i融剤は抗生物質であるエリスロマイシンに比べ
ればその抗結節作用がやや低いが、この発明の抗顛融剤
は抗生物質ではないため抗生物質にみられるような副作
用(体内微生物相の撹乱、耐性菌の出現)がなく、長期
間連用しても全く問題はない。さらに、この発明の接結
融剤は極めて低濃度でミュータンス菌の生育を阻止する
ことができるため、微量の使用量で大きな抗蘭蝕効果を
得ることができるのである。
As described above, the binding agent of the present invention does not cause any side effects because it is made of highly safe flavor components that are widely and actually used in the food industry and the like. That is, the anti-fluxing agent of this invention has a slightly lower anti-nodulation effect than the antibiotic erythromycin, but since the anti-fluxing agent of this invention is not an antibiotic, it does not have the same effect as that found in antibiotics. There are no side effects (disturbance of the body's microflora, appearance of resistant bacteria), and there is no problem at all even when used continuously for a long period of time. Furthermore, since the welding agent of the present invention can inhibit the growth of Streptococcus mutans at an extremely low concentration, a large anti-orchidial corrosion effect can be obtained with a small amount of use.

このように、この発明の接結融剤は、香料成分であって
しかも微量の使用量で優れた抗蘭蝕効果が得られるだめ
、うがい薬、トローチ、はみかき。
As described above, the binding agent of the present invention is a fragrance ingredient and can be used in mouthwashes, troches, and toothpastes because it has excellent anti-orchidial effects even when used in a small amount.

チューインガム等を賦香すると同時に抗結節効果も発揮
しつるのである。そして、その使用により従来の抗生物
質のような副作用が全く生じないのであり、長期間の連
用に充分に耐えうる極めて実用性の高いものである。
It not only adds flavor to chewing gum, but also has an anti-knot effect. Moreover, its use does not cause any side effects unlike those of conventional antibiotics, and it is highly practical as it can withstand long-term continuous use.

つぎに、実施例について説明する。Next, examples will be described.

〔実施例〕〔Example〕

前表に記載されたd−デカラクトン、d−ドデカラクト
ン、d−ウンデカラクトン、d−)リデカラクトン、d
−テトラデカラクトンの等景況合物を対象とし、これの
ミュータンス菌に対する有効生育濃度を調べたところ、
その有効生育濃度濃度は、。oo(抗ミュータンス菌活
性4000 )であった。この混合物は濃厚なミルクの
風味を有しており、その5%アルコール溶液を濃度10
係の蔗糖溶液に一工一の割合で添加して口に含んでも違
000 和感および刺激は感じられなかった。なお、上記ラクト
ン類の相加平均の抗ミュータンス菌活性は1600であ
り、上記実施例混合物の抗ミュータンス菌活性はそれよ
りもけるかに大きいことより、混合による相乗効果が認
められる。
d-decalactone, d-dodecalactone, d-undecalactone, d-)ridecalactone, d-) listed in the previous table
- When we investigated the effective growth concentration of tetradecalactone against S. mutans, we found that
Its effective growth concentration concentration is. oo (anti-Streptococcus mutans activity 4000). This mixture has a strong milk flavor, and its 5% alcohol solution has a concentration of 10
Even when I added it to my sucrose solution at a ratio of 1 part to 1 part and put it in my mouth, I did not feel any discomfort or irritation. The arithmetic mean anti-Streptococcus mutans activity of the above lactones is 1600, and the anti-Streptococcus mutans activity of the mixture of the above Examples is much higher than that, which indicates a synergistic effect due to the mixture.

特許出願人カネボウ食品株式会社Patent applicant Kanebo Foods Co., Ltd.

Claims (2)

【特許請求の範囲】[Claims] (1)  ラクトンからなることを特徴とする抗結節剤
(1) An anti-nodulation agent characterized by comprising a lactone.
(2)  ラクトンが、d−デカラクトン、d−ドデカ
ラクトン、d−ウンデカラクトン、d−トリデカラクト
ンおよびd−テトラデカラクトンからなる群から選ばれ
た少なくとも一つのラクトンである特許請求の範囲第1
項記載の抗結節剤。
(2) The lactone is at least one lactone selected from the group consisting of d-decalactone, d-dodecalactone, d-undecalactone, d-tridecalactone, and d-tetradecalactone. 1
Anti-nodulation agent as described in section.
JP5120383A 1983-03-26 1983-03-26 Cariostatic agent Granted JPS59175428A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5120383A JPS59175428A (en) 1983-03-26 1983-03-26 Cariostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5120383A JPS59175428A (en) 1983-03-26 1983-03-26 Cariostatic agent

Publications (2)

Publication Number Publication Date
JPS59175428A true JPS59175428A (en) 1984-10-04
JPH0320364B2 JPH0320364B2 (en) 1991-03-19

Family

ID=12880336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5120383A Granted JPS59175428A (en) 1983-03-26 1983-03-26 Cariostatic agent

Country Status (1)

Country Link
JP (1) JPS59175428A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006255781A (en) * 2005-02-16 2006-09-28 Honda Motor Co Ltd Draw forming device
JP2012246235A (en) * 2011-05-26 2012-12-13 Kao Corp Autoinducer-2 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985870A (en) * 1971-03-24 1976-10-12 Pfanstiehl Laboratories, Inc. Toothpastes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985870A (en) * 1971-03-24 1976-10-12 Pfanstiehl Laboratories, Inc. Toothpastes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006255781A (en) * 2005-02-16 2006-09-28 Honda Motor Co Ltd Draw forming device
JP2012246235A (en) * 2011-05-26 2012-12-13 Kao Corp Autoinducer-2 inhibitor

Also Published As

Publication number Publication date
JPH0320364B2 (en) 1991-03-19

Similar Documents

Publication Publication Date Title
US5104644A (en) Mouthrinse composition
JP3969272B2 (en) Anti-caries and anti-periodontal disease composition
JPH0138084B2 (en)
KR20000016351A (en) Antimicrobial agents for oral hygiene products
JPH0140005B2 (en)
JP3614479B2 (en) Periodontal disease-causing bacteria or caries-causing bacteria inhibitor, oral composition and food containing them
JPS61171423A (en) Drug for alleviating dental caries and periodontosis
Bou-Chacra et al. Antimicrobial activity of four different dental gel formulas on cariogenic bacteria evaluated using the linear regression method
JPH03240721A (en) Composition for oral cavity
JPH0217524B2 (en)
JPH0432047B2 (en)
JPH0639375B2 (en) Anti-caries agent
JP7445910B2 (en) Oral compositions, oral care products, and foods containing oral resident bacteria regulators
JPS59175428A (en) Cariostatic agent
US20040265247A1 (en) Mouth rinse composition
WO2021079921A1 (en) Growth inhibitor for pathogenic bacteria in oral cavity, oral microflora improver, and composition for oral cavity
JPS59175423A (en) Cariostatic agent
JP2000327581A (en) Composition for sterilizing oral cavity
JP6921655B2 (en) Protease inhibitors, biofilm formation inhibitors, and oral compositions
US20160213604A1 (en) Compositions and methods for reducing caries-causing oral bacteria
JP6918529B2 (en) Oral composition
JP6389212B2 (en) Oral composition
JPH0288518A (en) Composition for oral cavity application
Gunawan et al. Toothpaste Formulation Combination of Andaliman Fruit and Kecombrang Flowers as a Cleaner and Antibacterial
DE3104189C2 (en)